Posted 8/12/2013 6:59 PM (GMT 0)
I'm just going to paste Ralph's last post which I think is a good starting point for rd 2. Hope he doesn't mind that i'm quoting him to bring his very important thread back tot he point it merits.
"The thread was started with the intention of including some reason and logic to the screening/over diagnosis/overtreatment discussion. The statement from the Melbourne conference represents that in my view.
My wish is that their statement is an indication that reducing screening is not the best option for reducing the amount of overtreatment that currently exists and would be in detriment of the actual gain in mortality reduction associated with early detection and more effective treatment at such stage of diagnosis.
Their statement contains some important words for all of us to consider:
“An important goal when considering early detection of prostate cancer today, is to maintain the gains that have been made in survival over the past thirty years since the introduction of PSA testing, while minimizing the harms associated with over-diagnosis and over-treatment. This is already happening in Australia where over 40% of patients with low-risk prostate cancer are managed with surveillance or watchful waiting [10], and in Sweden where 59% of very low risk patients are on active surveillance. This is also reflected in current guidelines from the EAU, NCCN and other expert bodies.
Abandonment of PSA testing as recommended by the USPSTF, would lead to a large increase in men presenting with advanced prostate cancer and a reversal of the gains made in prostate cancer mortality over the past three decades.
However, any discussion about surveillance is predicated on having a diagnosis of early prostate cancer in the first instance. As Dr Joseph Smith editorialized in the Journal of Urology following the publication of the ERSPC and PLCO trials, “treatment or non-treatment decisions can be made once a cancer is found, but not knowing about it in the first place surely burns bridges”[11]. A key strategy therefore is to continue to offer well-informed men the opportunity to be diagnosed early, while minimizing harms by avoiding intervention in those men at low risk of disease progression. This consensus statement provides some guidance to help achieve these goals. “
Signatories:
A/Professor Declan G Murphy, University of Melbourne, Peter MacCallum Cancer Centre, Melbourne, Australia
Professor Tony Costello, University of Melbourne, Royal Melbourne Hospital, Melbourne, Australia
Dr Patrick C Walsh, The James Buchanan Brady Urological Institute, Johns Hopkins University, USA
Dr Thomas Ahlering, University of California, Irvine, School of Medicine, USA
Dr William C Catalona, Northwestern University Feinberg School of Medicine, USA
Professor Noel Clarke, Manchester University, The Christie Hospital, Manchester, UK
Dr Matthew Cooperberg, University of California San Francisco, Helen Diller Family Comprehensive Cancer Centre, USA
Dr David Gillatt, University of Bristol, Bristol Urological Institute, Bristol, UK
Dr Martin Gleave, University of British Columbia, The Vancouver Prostate Centre, Vancouver, Canada
Dr Stacy Loeb, New York University, USA
Dr Monique Roobol, Erasmus University Medical Centre, Rotterdam, The Netherlands
[10] Evans SM, Millar JL, Davis ID, Murphy DG, Bolton DM, Giles GG, et al. Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011. Med J Aust. 2013;198:540-5.
Peace to all...
RalphV"